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Abstract
Background: Many copy number variants (CNVs) are documented to be associated with neuropsychiatric
disorders, including intellectual disability, autism, epilepsy, schizophrenia, and bipolar disorder. Chromosomal
deletions of 1q21.1, 3q29, 15q13.3, 22q11.2, and NRXN1 and duplications of 15q11-q13 (maternal), 16p11, and
16p13.3 have the strongest association with schizophrenia. We hypothesized that cases with both schizophrenia
and epilepsy would have a higher frequency of disease-associated CNVs and would represent an enriched sample
for detection of other mutations associated with schizophrenia.
Methods: We used array comparative genomic hybridization (CGH) to analyze 235 individuals with both
schizophrenia and epilepsy, 80 with bipolar disorder and epilepsy, and 191 controls.
Results: We detected 10 schizophrenia plus epilepsy cases in 235 (4.3%) with the above mentioned CNVs
compared to 0 in 191 controls (p = 0.003). Other likely pathological findings in schizophrenia plus epilepsy cases
included 1 deletion 16p13 and 1 duplication 7q11.23 for a total of 12/235 (5.1%) while a possibly pathogenic
duplication of 22q11.2 was found in one control for a total of 1 in 191 (0.5%) controls (p = 0.008). The rate of
abnormality in the schizophrenia plus epilepsy of 10/235 for the more definite CNVs compares to a rate of 75/7336
for these same CNVs in a series of unselected schizophrenia cases (p = 0.0004).
Conclusion: We found a statistically significant increase in the frequency of CNVs known or likely to be associated
with schizophrenia in individuals with both schizophrenia and epilepsy compared to controls. We found an overall
5.1% detection rate of likely pathological findings which is the highest frequency of such findings in a series of
schizophrenia patients to date. This evidence suggests that the frequency of disease-associated CNVs in patients
with both schizophrenia and epilepsy is significantly higher than for unselected schizophrenia.
Background
The genetic contribution to the etiology of schizophre-
nia is significant, but the full molecular basis of the
genetic factors remains incompletely defined. Since at
least 1992 [1], it has been known that deletion of chro-
mosome 22q11.2 is associated with schizophrenia with a
very substantial relative risk. One study of 78 adults
with deletion 22q11.2 found that 22.6% had
schizophrenia [2]. Recurrent seizures were found in
39.7%, which may be explained in part by the hypocalce-
mia associated with this phenotype. In 2008, two studies
[3,4] found that chromosomal deletions of 1q21.1,
15q13.3, and 22q11.2 were associated with markedly
increased risk of schizophrenia; one report but not the
other also suggested a role for deletion 15q11.2. These
three most frequent deletions were found in 0.21%,
0.20%, and 0.26% respectively of the schizophrenic
populations studied, and they are also associated with
intellectual disability and autism [5,6]. It is quite
remarkable that each of these CNVs can be associated
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with a wide range of phenotypes including intellectual
disability, autism, schizophrenia, and epilepsy [7]. Dele-
tion 15q13.3 is also reported to be present in as many
as 1% of individuals with idiopathic generalized epilepsy
[8]. For the 15q13.3 deletion, the CHRNA7 gene encod-
ing the a7 subunit of the neuronal nicotinic receptor is
a strong candidate gene mediating the phenotypic
effects, as further supported by smaller deletions causing
similar phenotypes [9]. The other two deletions (1q21.1
and 22q11.2) encompass many genes with no one gene
yet strongly implicated as mediating the phenotypic
effects. Other chromosomal mutations have also been
found in schizophrenia such as deletions of 3q29 and
NRXN1 and duplications of 15q11-q13 (maternal),
16p11.2, and 16p13.3 [10-14]. Deletions of chromosome
16p11.2 are particularly common in autism [15,16], and
there is evidence that reciprocal duplications are asso-
ciated with schizophrenia [11]. There is also evidence
that loss-of-function mutations in individual genes can
be associated with autism and/or schizophrenia. These
genes include or may include DISC1, NRXN1, PDE4B,
NPAS3, CNTNAP2, and APBA2; see Sebat et al. [7] for
bibliography.
We reasoned that the frequency of detectable CNVs
associated with schizophrenia might be higher in sub-
jects with both schizophrenia and epilepsy compared to
either phenotype alone. There is a report that patients
with schizophrenia have an 11-fold increase in the pre-
valence of comorbid epilepsy [17]. We analyzed DNA
from subjects with both schizophrenia and idiopathic
epilepsy or with bipolar disorder and idiopathic epilepsy




DNA samples from 235 subjects with both schizophre-
nia and idiopathic epilepsy, 80 subjects with both bipo-
lar disorder and idiopathic epilepsy, and 191 controls
derived from cultured lymphoblasts, were obtained from
the National Institute of Mental Health Human Genetics
Initiative (NIMH-HGI). The NIMH website for this col-
lection https://www.nimhgenetics.org/nimh_human_gen-
etics_initiative/ reports that the establishment of a
diagnosis of schizophrenia or bipolar disorder was based
on DSM-III-R and DSM-IV criteria following a systema-
tic and comprehensive examination of multiple sources
of available information obtained from relatives, medical
records, and direct assessment using the Diagnostic
Interview for Genetic Studies for each patient. A self-
reported questionnaire completed by the subjects was
used to identify individuals who also had epilepsy in
addition to a diagnosis of schizophrenia or bipolar disor-
der. Subjects reporting seizures secondary to causes
such as trauma, medication, and/or polydypsia were
excluded. Some patients with self-reported seizures but
no further detail about etiology of their seizures were
included. Ethnicity for the schizophrenia plus epilepsy
samples was 135 Caucasian, 62 black, 22 Asian, 8 Hispa-
nic, and 6 other. Ethnicity for the bipolar plus epilepsy
was 77 Caucasian, 1 other, and 2 unknown. Ethnicity
for the controls was 100% Caucasian. We screened Cau-
casian control individuals for psychiatric symptoms
based on their self reported questionnaire. We chose to
exclude controls with even modest or questionable
behavioral findings in an attempt to exclude individuals
who might have mild manifestations of a deleterious
CNV. The rationale was to obtain a control group with
under-representation of any behavioral abnormalities.
Control individuals were excluded if they saw a doctor
and took medication or used drugs and alcohol to deal
with their depression or anxiety, if they reported any
behaviors suggestive of obsessive compulsive disorder,
or if they had a history of substance and/or alcohol
abuse/dependence. We excluded 1284 samples out of
1920 leaving 636 control samples for study. Then 191 of
the 636 were selected at random for study. This high
exclusion rate was surprising, but it was already known
that lifetime prevalences for depressive, anxiety, and
substance use diagnoses were higher than in some other
sample collections [18]. Additional information regard-
ing screening criteria can be found in Additional file 1.
Another study using these controls excluded far fewer
samples based on rescreening [19].
Array CGH
Blood collected from schizophrenia, bipolar disorder,
and control samples was used to establish lymphoblas-
toid cell lines and DNA was extracted by Rutgers Uni-
versity Cell and DNA Repository, Piscataway, NJ. Blood
DNA was not available for most samples, so it was not
possible to test whether results were only in lymphoblast
DNA and absent in blood DNA. All cases and controls
were hybridized with the same Caucasian male reference
DNA isolated from fresh blood. Although it is well
known that using DNA from lymphoblast cell-lines can
give rise to artifactual copy number changes [20,21],
these usually do not produce CNVs identical to those
known to cause neurobehavioral phenotypes and more
often involve aneuploidy, very large genomic changes, or
deletions at immunoglobulin genes.
Array CGH was performed on cases and controls with
once-used, stripped clinical v8.0 arrays from the Medical
Genetics Laboratory (MGL) at Baylor College of Medi-
cine (BCM). Specifically, the v8.0 array is a 180 K Agi-
lent oligonucleotide array with 30 kb backbone coverage
and exon by exon coverage for 1714 genes reported to
be associated with or cause disease or considered to be
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candidates for neurological disease association [22]
http://www.bcm.edu/geneticlabs/test_detail.cfm?test-
code=8655. The array was designed by Pawel Stankie-
wicz, March 2006 and manufactured by Agilent
Technology (Santa Clara, CA). Previously used slides
from both abnormal and normal cases were stripped by
boiling in a 5 mM potassium phosphate buffer solution
for 2 minutes. The reuse of clinical arrays provided a
major cost reduction for these studies and allowed for
comparison to a large body of clinical data using the
same array design. We have experience that the used
arrays detect known variants reliably if the Agilent DLR
score is less than 0.30. These data indicate that false
negative results would be rare. There is no significant
concern regarding false positive results, because all
CNVs were validated using new arrays with coverage
suitable for the putative CNV.
The procedures for DNA digestion, labeling, and
hybridization for the oligonucleotide arrays were per-
formed according to the manufacturers’ instructions,
with minor modifications [23]. Slides were scanned into
image files using the Agilent G2565 Microarray Scanner.
Scanned images were quantified using Agilent Feature
Extraction software (v10.7.3.), then analyzed for copy-
number change using our in-house analysis package, as
described previously [24-26]. All calls made with the in-
house software were visually inspected to assess their
validity. Additional information on analysis can be
found in Additional file 1.
Common CNVs, CNVs located in introns or in non-
genic regions, and calls less than one kb were noted in
the analysis but are not reported here. Common calls, as
defined by being seen more than 20 times in 20,000
cases analyzed by the Medical Genetics Laboratories at
Baylor College of Medicine, were also not included.
Array data has been deposited in the GEO database
under accession number GSE23703. All coordinates are
based on the Feb. 2009 UCSC Human Genome Browser
assembly (hg19).
All calls reported were validated on a variety of fresh,
higher resolution arrays, depending on the coverage of
the region in question and included: a custom Agilent 1
M array designed to cover the great majority of exons in
the genome (Celestion-Soper submitted manuscript),
Agilent SurePrint G3 Human CGH 4 × 180 catalog
array (design ID: 022060), and a gene targeted custom
arrays (all Agilent Technologies, Santa Clara, California,
USA). All arrays used in this study were designed and
analyzed based on UCSC hg18 (NCBI Build 36), March
2006. For CNVs that did not have adequate coverage on
the 4 × 180 Agilent catalog, custom Agilent 4 × 180 k
or 8 × 60 k arrays with focused coverage for the regions
of interest were designed using Agilent’s E-array data-
base. The array designs can be viewed on Agilent’s e-
array database https://earray.chem.agilent.com/earray/
(SSC Tiling v2.0: 027305, SSC Focused v3.0: 028249,
Focused v4.0: 028812).
CNVs found in our study were compared to those in
the DGV database http://projects.tcag.ca/variation/.
Entries in the DGV database that were smaller than or
overlapped for less than 10% of our calls were not
counted. IDENTICAL indicates one or more CNVs
were found in the database to be identical to our CNV
+or- 10% on either side. The publication by Levinson et
al. [19] analyzed most of the same NIMH samples
reported here. A tabulation of all CNV findings in indi-
vidual samples reported here is available from the corre-
sponding author.
Results and Discussion
DNA from 235 subjects with both schizophrenia and
idiopathic epilepsy, 80 subjects with bipolar disorder
and idiopathic epilepsy, and 191 controls was analyzed
using array CGH. Out of 235 subjects with both schizo-
phrenia and idiopathic epilepsy, we identified 10 CNVs
well established to be associated with schizophrenia (see
references in Background above), These included three
deletions of 1q21.1, one deletion of 2p16.3 (NRXN1),
one deletion of 15q13.3, two maternal duplications of
15q11-q13, and three deletions of 22q11.2 (Figure 1 and
Table 1). We also found two other CNVs that have a
well established role in other neuropsychiatric pheno-
types or epilepsy. These included a deletion of 16p13.1
which is associated with intellectual disability and more
recently with schizophrenia [27] and a duplication of
the Williams-Bueren syndrome region (7q11.23) which
is well documented to be associated with neuropsychia-
tric phenotypes [28]. In total we found 12 out of 235
cases of schizophrenia and epilepsy (5.1%) harbored
CNVs highly likely to have a significant association with
the disease phenotype. This is the highest detection rate
for pathological CNVs in any schizophrenia population
studied to date.
Among cases with schizophrenia plus epilepsy, we
identified many deletions of uncertain significance but
with some published link to neuropsychiatric disease.
Single cases of deletions were observed for 20p13,
CHRNB3, DLG2, GRIP1, and SLC1A1 (Figure 2 and
Table 2). A genome wide linkage analysis for autosomal
dominant schizophrenia within a single Israeli Arab ped-
igree demonstrated a significant linkage association with
20p13 [29] and a linkage analysis of 270 Irish high-den-
sity families with varying psychotic illnesses showed a
potential linkage of the behavioral phenotypes to a
region on 20p that includes 20p13 [30]. There are multi-
ple candidate genes in the linkage interval. CHRNB3, a
nicotinic receptor, is reported to be associated with
smoking behavior by GWAS [31] and to show linkage
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to epilepsy in one study [32]. DLG2 encodes a family
member of the membrane-associated guanylate kinase
(MAGUK) proteins which are part of the postsynaptic
density and interact with receptors, ion channels, and
other signaling proteins. Other members of the
postsynaptic density such as PSD95 and SAP97 are
reported to have altered expression in schizophrenia and
epilepsy [33-35]. GRIP1 is a member of the glutamate
receptor interacting proteins and has been reported to
show altered expression in schizophrenia brain [36,37].
Figure 1 Most frequent pathogenic microdeletions observed in NIMH cases with both schizophrenia and epilepsy. Three cases of
deletion 22q11.2 and three cases of deletion 1q21.1 are shown. Unique identifiers from the NIMH collection are provided. Low copy repeat
(LCR) regions and gene symbols are provided. Coordinates are based on hg19.
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A study of genotyped autistic patients and matched con-
trols showed an association of a SNP within a genomic
region of GRIP1 with autism [38]. Linkage to the region
containing, SLC1A1, a glutamate transporter, has been
reported for obsessive compulsive disorder [39,40], and
a SNP near SLC1A1 was reported to show association
with autism spectrum disorder [41].
Similarly, duplications of uncertain significance but
with some published link to neuropsychiatric disease
were found in five schizophrenia plus epilepsy cases.
These included duplications of 6q15, 16p13.2, 19p13.3,
CHRNA7, and SLC6A4 (Table 3). The 6q15 duplication
contains HTR1E which encodes a serotonin receptor
and has been suggested to be of interest in suicide [42],
and attention-deficit/hyperactivity disorder [43].
The16p13.2 region contains ABAT which encodes a g-
aminobutyrate transaminase that is responsible for the
conversion of GABA to succinic semialdehyde (OMIM
137150). This locus has been reported to show altered
expression in epilepsy [44] and genetic association in
autism [45]. There is some evidence for linkage to aut-
ism at 19p13.3 in a Finnish pedigree [46]. CHRNA7
small duplications are common in the population and
may have some pathogenic significance [47], and at least
Table 1 CNV abnormalities of likely significance in cases with both schizophrenia and epilepsy.
NIMH ID Sex Chr. Start Size (bp) CNV Genes Validation DGV
35-70486-01 M 1q21.1 145009580 2814627 Loss 36 Cat Identical
147-2042-001 M 1q21.1 146506369 1317838 Loss 15 Cat Identical
143-2166-001 M 1q21.1 145388414 444581 Loss 17 Cat Identical
147-2403-001 F 2p16.3 50579352 428671 Loss NRXN1 Cat Identical
143-2074-001 M 7q11.23 72876647 563297 Gain 15 Cus4 Identical
32-11055 F 15q11-q13 21213950 4994696 Gain 30 genes, SNORDs Cat Identical
144-1023-001 M 15q11-q13 22842145 6189545 Gain 28 genes, SNORDs Cat Identical
142-1340-001 M 15q13.3 30587903 2320279 Loss 16 MLPA Identical
145-1243-001 M 16p13.11 15131782 1117825 Loss 10 Cat Identical
145-1122-001 M 22q11.21 18894894 2569166 Loss 58 Cat Identical
143-2379-001 M 22q11.21 18894894 2569166 Loss 58 Cat Identical
143-2623-001 M 22q11.21 18890615 1469118 Loss 36 SNP Identical
Abbreviations: M, male; F, female; Chr, chromosome; bp, base pair; CNV, copy number variant; DGV, Database of genomic variants. For validation: Cat = 4 × 180
Agilent catalog array; Cus1, Cus2, etc. refer to custom designed focused arrays 1, 2, etc.; MLPA-multiplex ligation-dependent probe amplification, SNP-Illumina
610 quad SNP catalog array.
Figure 2 Microdeletions of uncertain significance with some published link to neuropsychiatric disease observed in NIMH cases with
both schizophrenia and epilepsy. Deletions on specific Agilent custom arrays for validation are shown involving an exon of DLG2, an exon of
SLC1A1, an exon of GRIP1, and multiple genes at the 20p13 locus as labeled. The regions of deletion are demarcated by red rectangles. Each dot
represents an oligonucleotide, green for deleted and black for normal copy number.
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one was reported in schizophrenia [3]. We identified
two CHRNA7 duplications in schizophrenia patients and
one in a bipolar disorder patient; however, we also
found one in our controls. This duplication is quite
common, but its phenotypic significance is not clear
[47]. SLC6A4 encodes a protein involved in the trans-
port of serotonin and there is a report of genetic asso-
ciation with schizophrenia [48]. Additional findings of
unknown significance in schizophrenia plus epilepsy
samples are listed in Table 3.
Table 2 CNVs abnormalities of possible significance in cases with both schizophrenia and epilepsy.
NIMH ID Sex Chr. Start Size (bp) CNV Genes Validation DGV
140-2082-001 M 8p11.21 42582092 7817 Loss CHRNB3 Cus2 None
143-2447-001 M 9p24.2 4409405 134869 Loss SLC1A1 Cus2 2 overlap
144-1472-001 M 11q14.1 84188228 482969 Loss DLG2 Cus2 None
147-2093-001 M 12q14.3 67049795 150443 Loss GRIP1 Cus4 None
144-1461-001 M 20p13 3897943 1039259 Loss 12 Cat None
Abbreviations: As in Table 1.
Table 3 CNVs of unknown significance in schizophrenia and epilepsy samples
NIMH ID Sex Chr. Start Size (bp) Genes Validation DGV
142-1320-001 M 2p21 44531130 68210 Loss SLC3A1, PREPL, C3orf34 Cus1 2 overlap
149-1129-001 F 2p16.1 56091146 13954 Gain EFEMP1 Cus4 None
49-1020-001a F 4q28.2 129774971 154534 Gain PHF17, SCLT1 Cus4 Identical
53-10259 F 6p22.3 17465076 387198 Gain 4 Cus4 1 overlap
70-11763 F 6p22.3 22272906 148050 Loss PRL Cus4 1 overlap
144-1291-001 M 6q14.1 76607923 25447 Loss MYO6, IMPG1 Cus1 None
54-10078 F 6q15 87456408 730692 Gain 9 Cus4 3 overlap
144-1096-001 M 7q11.22 71029067 240023 Gain WBSCR17, CALN1 Cat Identical
142-1006-001 F 7q31.32 122364506 676522 Gain CADPS2, TAS2R16, SLC13A1 Cus4 5 overlap
149-1114-001 M 8q21 84569675 844484 Loss RALYL Cat 1 overlap
54-10151a M 9p24.3 115980 471438 Loss 5 Cat Common
141-0680-001 F 9p24.1 6451073 394797 Gain UHRF2, GLDC, KDM4C Cus4 4 overlap
142-1340-001 M 12p13.33 1949926 37541 Loss CACNA2D4 Cus1 1 overlap
143-2467-001 M 12p13.33 1949882 34631 Loss CACNA2D4 Cus1 1 overlap
146-2019-001 M 12p11.22 29009447 562052 Gain FAR2, ERGIC2 Cat 1 overlap
142-1274-001 M 13q34 110957062 275718 Gain COL4A2, RAB20 Cus4 1 overlap
140-2154-001 M 13q34 114476840 148441 Gain FLJ44054, GAS6, FAM70B Cus4 2 overlap
144-1307-001 M 15q11.2 22842143 244550 Gain TUBGCP5, CYFIP1, NIPA2,NIPA1 b MLPA Common
147-2423-001 M 15q13.3 32296138 142658 Gain CHRNA7 b MLPA Common
35-71412-02 M 15q13.3 32296138 164344 Gain CHRNA7 b MLPA Common
42-1051-002 F 16p13.2 8969708 103443 Gain USP7 Cat 1 overlap
143-2384-001 M 16p13.2 8581817 830333 Gain 9 Cat 1 overlap
147-2080-001 M 16p13.12 12771677 165576 Loss CPPED1 Cat 2 overlap
54-10151a M 17p13.3 2995336 422668 Gain 14 Cat 1 overlap
54-10151a M 17p13.2 3743015 483613 Gain 8b Cat 2 overlap
49-1020-001a F 17p12 14111831 1330176 Gain 9 Cat Identical
142-1278-001 M 17p12 14897946 148020 Loss CDRT7 Cus4 Identical
144-1594-001 M 17p11.2 21311601 50888 Gain KCNJ12b Cus3 Identical
148-2171-001 M 17q11.2 28524944 21111 Gain SLC6A4 Cus1 None
35-08447-02 M 18q11-q12 24744073 458607 Gain CHST9 Cus4 None
30-11632 F 19p13.3 6427852 429890 Gain 14 Cus4 None
143-2526-001 M 19q13.42 54646013 1707820 Gain 87 Cat 7 overlap
Abbreviations: As in Table 1.
a denotes samples having more than one CNV.
b denotes cases which had a similar call to CNV found in controls.
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For the 80 subjects with both bipolar disorder and
epilepsy, only 13 CNVs were identified but the number
of cases studied was relatively small. Bipolar disorder
was previously reported to have a lower CNV detection
rate as compared to schizophrenia [49]. The findings in
patients with both bipolar disorder and epilepsy are
listed and discussed in Additional file 1 Table S1.
The findings in the cases were compared to findings
in the NIMH controls screened to reduce the frequency
of psychiatric symptoms as discussed above. One control
was found to have a duplication of 22q11.2. Duplica-
tions of 22q11.2 show incomplete penetrance and cause
a highly variable phenotype of neurocognitive dysfunc-
tion [50,51], although there is at least one report sug-
gesting an association with schizophrenia [10]. Although
we screened out a large fraction of controls based on
psychiatric symptoms, this individual passed that screen.
Yet this male control with duplication 22q11.2 is note-
worthy for self-reporting two episodes of depression
lasting for four weeks accompanied by use of drugs or
alcohol more than once for these problems. He also
reported that drinking of alcohol interfered with school,
job or home life once or twice in the past. He reported
the use amphetamines, marijuana, and cocaine, and that
this use interfered with school, job or home life 3-5
times. (We excluded controls reporting such drug use 6
or more times.) We also found a 15q11.2 deletion in
one control sample, and though this CNV is reported to
be associated with schizophrenia by some authors [3],
the penetrance is quite low [12].
Other findings in controls involving loci of some neu-
robehavioral relevance included deletions of CNTN4
and GABRR1 and duplications of 15q11.2. Table 4 for
complete list of CNVs found in controls.
We wished to assess whether the frequency of dis-
ease-related CNVs was significantly more frequent in
patients with schizophrenia and epilepsy compared to
controls from the same repository and tested on the
same array platform. For this assessment, we accepted
the following CNVs as being known to be associated
with schizophrenia based on published data [12,19]:
deletions of 1q21.1, 3q29, 15q13.3, 22q11.2, and
NRXN1 and duplications of 15q11-q13 (maternal),
16p11, and 16p13.3. We included maternal duplica-
tions of 15q11-q13 in this group because of the exten-
sive literature linking it to autism and to epilepsy and
based on recent reports of its occurrence in schizo-
phrenia [14,52]. We detected 10 schizophrenia plus
epilepsy cases in 235 (4.3%) with the above mentioned
CNVs compared to 0 in 191 controls (Fisher’s exact
test, p = 0.003). Other likely pathological findings in
schizophrenia plus epilepsy cases included 1 deletion
16p13 and 1 duplication 7q11.23 for a total of 12/235
(5.1%) while a possibly pathogenic duplication of
22q11.2 was found in one control for a total of 1 in
191 (0.5%) controls (Fisher’s exact test, p = 0.008). We
also wished to assess whether our data supported the
hypothesis that disease-associated CNVs would be
more common in cases of schizophrenia and epilepsy
compared to unselected schizophrenia. The rate of
abnormality in the schizophrenia plus epilepsy of 10/
235 for the more definite CNVs compares to a rate of
75/7336 based on supplemental data from Levinson et
al. [19] for these same CNVs in a series of unselected
schizophrenia cases (Fisher’s exact test, p = 0.0004).
There are weaknesses in the current study including
the use of cell line DNA rather than blood derived
DNA, self-reporting of epilepsy findings, less than opti-
mal phenotypic information, lack of availability of par-
ental DNA, and lack of complete matching of ethnicity
of cases and controls. Despite these difficulties, the
observed differences are so substantial that they indi-
cate that the frequency of disease-associated CNVs is
significantly higher than any control group and signifi-
cantly higher than in any series of unselected schizo-
phrenia cases. Based on these results, clinicians can
reasonably expect a pathological CNV detection rate of
about 5% if they study patients with both schizophre-
nia and idiopathic epilepsy. In addition, all of these
samples are readily available to diagnostic laboratories
for validation of testing. These data, along with pro-
gress in whole exome and whole genome sequencing,
suggest that the time is approaching when molecular
genetic analysis of schizophrenia patients will be a
clinically useful activity.
Conclusions
The data presented here strongly suggest that disease-
associated CNVs were present at a significantly higher
frequency in cases with both schizophrenia and epilepsy
compared to control samples from the same repository.
In addition, disease-associated CNVs were found at a
significantly higher frequency in schizophrenia plus epi-
lepsy cases than in larger series of unselected schizo-
phrenia. Although many geneticists would argue that
chromosomal microarray analysis (CMA) is clinically
useful today in patients with either schizophrenia or
idiopathic epilepsy alone, the case for CMA testing is
more compelling for individuals with both schizophrenia
and epilepsy. The detection rate of clinically significant
abnormalities is increasing with exon by exon coverage
for hundreds of genes [22]. Although the frequency of
pathological finding may be regarded by some as rela-
tively low, definitive abnormalities can clarify diagnosis,
inform genetic counseling, and potentially lead to CNV-
specific management [53].
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Additional material
Additional file 1: Supplementary. Additional details regarding
methods, data analysis, and validation of findings as well as other results
not discussed in the text can be found here.
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150-12491 M 7p22.1 5667980 255505 Gain RNF216, ZNF815, OCM Cat 2 overlap
150-11643 F 7q21.13 88200226 354752 Loss ZNF804B, MGC26647 Cus4 8 overlap
150-10750a F 8p21.3 22211184 167245 Gain PIWIL2, SLC39A14, PPP3CC Cus4 2 overlap
150-12293 M 8q12.1 56682642 214806 Gain TMEM68, TGS1, LYN, RPS20 Cat 4 overlap
150-12964 M 9q21.32 86522765 193620 Gain 5 genes Cus4 3 overlap
150-10354 M 9q31.1 105642367 226151 Loss CYLC2 Cus4 1 overlap
150-10750a F 9q34.3 140374217 229402 Gain 9 genes Cus4 None
150-12487 M 12q12 40789970 3711960 Gain 13 genes Cat None
150-12111a M 12q24.12 112181037 136012 Gain ACAD10, ALDH2, C12orf47, MAPKAPK5 Cus4 None
150-10678 F 12q24.21 116367980 170923 Gain MED13L Cus4 1 overlap
150-10629 M 13q33.1 103192748 327792 Gain 7 genes Cat None
150-12138 M 15q11.2 22842143 244550 Gain TUBGCP5, CYFIP1, NIPA2, NIPA1 b MLPA Common
150-11886 M 15q11.2 22842143 244550 Gain TUBGCP5, CYFIP1, NIPA2, NIPA1 b Cat Common
150-12900 M 15q11.2 22842143 244550 Loss TUBGCP5, CYFIP1, NIPA2, NIPA1 MLPA Common
150-11785 F 15q13.3 31730445 694760 Gain CHRNA7 c Cat Common
150-11943 M 15q15.1 42656727 32418 Loss CAPN3 Cus4 None
150-12111a M 16p13.3 2147596 18151 Gain PKD1 Cus4 3 overlap
150-12420 M 17p13.2 4027661 492396 Gain 10 genesb Cat 4 overlap
150-10080 M 17p13.1 9993838 416496 Gain 5 genes Cat None
150-12837 M 17p11.2 21195549 306380 Gain MAP2K3, KCNJ12, C17orf51b Cat 13 overlap
150-12522 M 19q13.11 32809424 217110 Loss ZNF507, DPY19L3 Cus4 None
150-10660 F 21q22 35720798 185606 Gain KCNE2, FAM165B, KCNE1, RCAN1 Cus4 Identical
150-10685 M 22q11.21 18900180 2901481 Gain 50 genes Cat Common
150-10702 M Xp22.12 19563240 384858 Gain SH3KBP1, CXorf23 Cat None
150-12093 M Yp11.2 9523339 126272 Gain 8 genes Cus4 None
Abbreviations: As in Table 1.
a denotes samples having more than one CNV
b denotes controls which had a similar call to CNV found in cases
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